InsidersTradesSigma
申报总数
公司
▲ 买入（4 笔）
▼ 卖出（2 笔）
内部人交易记录
董事已披露买入
4
已披露卖出
2
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the detailed record of transactions filed by Rowland Charles A Jr, 董事. Director active across 5 companies, notably Blueprint Medicines Corp. In total, 13 filings have been recorded. Breakdown: 4 buys · 2 sells. Total volume traded: €508k. Activity tracked since 2 June 2021. The latest transaction was filed on 2 January 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Rowland Charles A Jr
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报13 总计
53,475 股Common StockSEC:0001104659-26-012196:0
3,150 股0Common Stock, par value $0.00001 per shareSEC:0001193125-26-003110:0
16,000 股@ US$4.4860.8% 占其流量Common Stock, par value $0.00001 per shareSEC:0001193125-25-254300:0
12,294 股Ordinary SharesSEC:0000950170-24-007074:0
192,960 股@ US$1.3145.9% 占其流量Common StockSEC:0001415889-23-015864:0
标准退出：2024年2月29日 (T+90)
40,000 股@ US$1.08100.0% 占其流量Common Stock, par value $0.00001 per shareSEC:0001209191-23-030796:0
15,750 股@ US$5.2616.3% 占其流量Common StockSEC:0001415889-22-009796:0
标准退出：2022年12月18日 (T+90)
17,147 股@ US$5.4118.4% 占其流量Common StockSEC:0001415889-22-009776:0
标准退出：2022年12月14日 (T+90)
18,784 股@ US$5.20419.4% 占其流量Common StockSEC:0001415889-22-009671:0
标准退出：2022年12月12日 (T+90)
8,496 股@ US$0.17548.0% 占其流量Ordinary SharesSEC:0001104659-22-085790:0
777 股@ US$1.2035.1% 占其流量Ordinary SharesSEC:0001104659-21-100288:0
17,500 股0Ordinary SharesSEC:0001104659-21-098427:0
2,250 股0Common StockSEC:0001179110-21-006417:0
13 条申报中的 13 条
About Rowland Charles A Jr
Rowland Charles A Jr is Administrateur and is reported in 13 filings in total. In the 13 sampled recent filings, the attributed transactions run from 2021-06-04 to 2026-02-09, with EUR 505477 of buys and EUR 2234 of sells. He is listed as Director at Generation Bio Co., Viking Therapeutics, Inc., Nabriva Therapeutics plc, Orchard Therapeutics plc, and Blueprint Medicines Corp.
